{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T20:26:44Z","timestamp":1787344004385,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Health Econ"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Economic evaluations often rely on immature data to evaluate cost-effectiveness of new treatments. Pembrolizumab was approved for advanced non-small cell lung cancer with high PD-L1 expression based on interim data from the KEYNOTE-024 trial. Using 5-year follow-up data, we re-evaluated the cost-effectiveness analysis to assess optimal survival models and their impact on the incremental cost-effectiveness ratio (ICER).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A partitioned survival model was developed from the national payer\u2019s perspective. Standard parametric distribution (SPD) models and excess hazard (EH) models were fitted to digitally reconstructed overall survival (OS) and progression-free survival (PFS) data from the 11-month interim and 5-year follow-up data from KEYNOTE-024. EH models incorporated general population mortality (GPM) rates to ensure stability and consistency in modelling OS and PFS. Model inputs were primarily derived from the prior assessment by the Swedish Health Technology Assessment agency. Uncertainties around survival models and inputs were examined in probabilistic sensitivity analyses (PSA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We demonstrated that incorporating the relative survival framework, using EH models, provided a more suitable modelling approach than SPD models when applied to immature survival data from a clinical trial. The SPD exponential models produced overly pessimistic projections, while the SPD log-normal models produced overly optimistic projections. The EH log-normal models without a cure assumption aligned closely with the follow-up data, producing realistic and consistent projections across interim and follow-up data. Scatter plots from the EH models exhibited reduced variability than the SPD models in PSA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Model selection should prioritize realistic survival projections with the use of EH models that incorporate GPM adjustment potentially preferred over SPD models. Models that accommodate waning disease-specific mortality with or without a cure assumption should be considered.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10198-026-01981-w","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T07:32:35Z","timestamp":1787297555000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The application of excess hazard models for plausible long-term extrapolation in cost-effectiveness: a re-evaluation of immunotherapy in advanced non-small cell lung cancer using the KEYNOTE-024 trial"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1587-3325","authenticated-orcid":false,"given":"Kun","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sweeting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Wilking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linus","family":"J\u00f6nsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"issue":"8","key":"1981_CR1","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.jval.2019.03.007","volume":"22","author":"A Kordecka","year":"2019","unstructured":"Kordecka, A. et al. 2019. Selection of Endpoints in Clinical Trials: Trends in European Marketing Authorization Practice in Oncological Indications. Value In Health : The Journal Of The International Society For Pharmacoeconomics And Outcomes Research 22(8):884\u2013890.","journal-title":"Value In Health : The Journal Of The International Society For Pharmacoeconomics And Outcomes Research"},{"issue":"4","key":"1981_CR2","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s41669-021-00279-2","volume":"5","author":"J Gordon","year":"2021","unstructured":"Gordon, J. et al. 2021. Non-Price-Related Determinants of Value and Access for Novel Non-small Cell Lung Cancer Treatments: A Cross-Country Review of HTA Decision Making. PharmacoEconomics - Open 5(4):701\u2013713.","journal-title":"PharmacoEconomics - Open"},{"key":"1981_CR3","unstructured":"National Institutute for Health and, and Care Excellence (NICE). 2021. NICE Strategy 2021 to 2026: Dynamic, Collaborative, Excellent. London. Available from: https:\/\/www.nice.org.uk\/strategy"},{"key":"1981_CR4","unstructured":"Pont\u00e9n J, R\u00f6nnholm G, Ski\u00f6ld P. PPRI Pharma Profile Sweden 2017. Stockholm: Dental and Pharmaceutical Benefits Agency (TLV), Pharmaceutical Pricing and Reimbursement Information (PPRI)."},{"issue":"19","key":"1981_CR5","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck, M. et al. 2016. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. New England Journal Of Medicine 375(19):1823\u20131833.","journal-title":"New England Journal Of Medicine"},{"key":"1981_CR6","unstructured":"Dental and Pharmaceutical Benefits Agency (TLV). 2017. Underlag f\u00f6r beslut i landstingen: Keytruda (pembrolizumab) \u2013 f\u00f6rsta linjens behandling av metastaserad icke-sm\u00e5cellig lungcancer. Stockholm. Dnr 3331\/2016."},{"issue":"21","key":"1981_CR7","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1200\/JCO.21.00174","volume":"39","author":"M Reck","year":"2021","unstructured":"Reck, M. et al. 2021. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score\u2009\u2265\u200950. Journal Of Clinical Oncology 39(21):2339\u20132349.","journal-title":"Journal Of Clinical Oncology"},{"key":"1981_CR8","unstructured":"Rutherford, M. J., Lambert, P.C., Sweeting, M. J. Pennington, R. Crowther, M. J. Abrams, K.R. 2020, NICE DSU Technical Support Document 21. Flexible Methods for Survival Analysis."},{"issue":"6","key":"1981_CR9","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1177\/0272989X231184247","volume":"43","author":"MJ Sweeting","year":"2023","unstructured":"Sweeting, M. J. et al. 2023. Survival Extrapolation Incorporating General Population Mortality Using Excess Hazard and Cure Models: A Tutorial. Medical Decision Making 43(6):737\u2013748.","journal-title":"Medical Decision Making"},{"issue":"3","key":"1981_CR10","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1177\/0272989X241227230","volume":"44","author":"EY Chen","year":"2024","unstructured":"Chen, E. Y. et al. 2024. Comparing Survival Extrapolation within All-Cause and Relative Survival Frameworks by Standard Parametric Models and Flexible Parametric Spline Models Using the Swedish Cancer Registry. Medical Decision Making 44(3):269\u2013282.","journal-title":"Medical Decision Making"},{"issue":"4","key":"1981_CR11","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1177\/0272989X16639900","volume":"37","author":"C Jackson","year":"2017","unstructured":"Jackson, C. et al. 2017. Extrapolating Survival from Randomized Trials Using External Data: A Review of Methods. Medical Decision Making 37(4):377\u2013390.","journal-title":"Medical Decision Making"},{"issue":"9","key":"1981_CR12","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.jval.2021.03.008","volume":"24","author":"I van Oostrum","year":"2021","unstructured":"van Oostrum, I. et al. 2021. Comparison of Parametric Survival Extrapolation Approaches Incorporating General Population Mortality for Adequate Health Technology Assessment of New Oncology Drugs. Value In Health : The Journal Of The International Society For Pharmacoeconomics And Outcomes Research 24(9):1294\u20131301.","journal-title":"Value In Health : The Journal Of The International Society For Pharmacoeconomics And Outcomes Research"},{"issue":"4","key":"1981_CR13","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/(SICI)1097-0258(19990228)18:4<441::AID-SIM23>3.0.CO;2-M","volume":"18","author":"R De Angelis","year":"1999","unstructured":"De Angelis, R. et al. 1999. Mixture models for cancer survival analysis: application to population-based data with covariates. Statistics In Medicine 18(4):441\u2013454.","journal-title":"Statistics In Medicine"},{"key":"1981_CR14","doi-asserted-by":"publisher","unstructured":"Andersson, T. M. L. et al. 2011. Estimating and modelling cure in population-based cancer studies within the framework of flexible parametric survival models. BMC Medical Research Methodology, 11(96). https:\/\/doi.org\/10.1186\/1471-2288-11-96","DOI":"10.1186\/1471-2288-11-96"},{"issue":"5","key":"1981_CR15","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1093\/ije\/dyaa128","volume":"49","author":"L Dal Maso","year":"2020","unstructured":"Dal Maso, L. et al. 2020. Cancer cure for 32 cancer types: results from the EUROCARE-5 study. International Journal Of Epidemiology 49(5):1517\u20131525.","journal-title":"International Journal Of Epidemiology"},{"issue":"11","key":"1981_CR16","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1001\/jamaoncol.2018.2761","volume":"4","author":"RL Dood","year":"2018","unstructured":"Dood, R. L. et al. 2018. Defining Survivorship Trajectories Across Patients With Solid Tumors: An Evidence-Based Approach. JAMA Oncol 4(11):1519\u20131526.","journal-title":"JAMA Oncol"},{"key":"1981_CR17","unstructured":"Woods, B. et al. 2017. NICE DSU Technical Support Document 19. Partitioned Survival Analysis for Decision Modelling in Health Care: A Critical Review. Decision Support Unit.Available from: http:\/\/www.nicedsu.org.uk"},{"key":"1981_CR18","unstructured":"National Institute for Health and Care Excellence (NICE). 2018. Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer. Technology appraisal guidance TA531. London: NICE. Available from: https:\/\/www.nice.org.uk\/guidance\/ta531"},{"key":"1981_CR19","unstructured":"TLV_3331_2016. 2017. Underlag f\u00f6r beslut i landstingen - Keytruda (pembrolizumab), Keytruda som monoterapi \u00e4r indicerat som f\u00f6rsta linjens behandling av metastaserad icke-sm\u00e5cellig lungcancer (NSCLC) hos vuxna vars tum\u00f6rer uttrycker PD-L1 i\u2009\u2265\u200950% av tum\u00f6rcellerna (tumour proportion score (TPS)\u2009\u2265\u200950%) och som inte \u00e4r positiva f\u00f6r mutationer i EGFR eller ALK. Tandv\u00e5rds- och l\u00e4kemedelsf\u00f6rm\u00e5nsverket (TLV)."},{"issue":"9","key":"1981_CR20","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1080\/13696998.2020.1775620","volume":"23","author":"MIA Aziz","year":"2020","unstructured":"Aziz, M. I. A. et al. 2020. Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer. Journal Of Medical Economics 23(9):952\u2013960.","journal-title":"Journal Of Medical Economics"},{"key":"1981_CR21","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.lungcan.2018.11.008","volume":"127","author":"C Chouaid","year":"2019","unstructured":"Chouaid, C. et al. 2019. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>\u200950%) metastatic squamous and non-squamous non-small cell lung cancer in France. Lung Cancer 127:44\u201352.","journal-title":"Lung Cancer"},{"issue":"8","key":"1981_CR22","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s40273-017-0527-z","volume":"35","author":"M Huang","year":"2017","unstructured":"Huang, M. et al. 2017. Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States. Pharmacoeconomics 35(8):831\u2013844.","journal-title":"Pharmacoeconomics"},{"key":"1981_CR23","doi-asserted-by":"publisher","first-page":"w20170","DOI":"10.4414\/smw.2019.20170","volume":"149","author":"A Bhadhuri","year":"2019","unstructured":"Bhadhuri, A. et al. 2019. Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland. Swiss Medical Weekly 149:w20170.","journal-title":"Swiss Medical Weekly"},{"issue":"4","key":"1981_CR24","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1080\/13696998.2019.1570221","volume":"22","author":"W Liao","year":"2019","unstructured":"Liao, W. et al. 2019. Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China. Journal Of Medical Economics 22(4):344\u2013349.","journal-title":"Journal Of Medical Economics"},{"issue":"3","key":"1981_CR25","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.jval.2022.10.012","volume":"26","author":"RW Chu","year":"2023","unstructured":"Chu, R. W. et al. 2023. Cost-Effectiveness of First-Line Pembrolizumab Monotherapy Versus Chemotherapy in High Programmed Death-Ligand 1 Advanced Non-Small Cell Lung Cancer in the Irish Healthcare Setting. Value In Health : The Journal Of The International Society For Pharmacoeconomics And Outcomes Research 26(3):402\u2013410.","journal-title":"Value In Health : The Journal Of The International Society For Pharmacoeconomics And Outcomes Research"},{"issue":"1","key":"1981_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot, P. et al. 2012. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Medical Research Methodology 12(1):9.","journal-title":"BMC Medical Research Methodology"},{"key":"1981_CR27","doi-asserted-by":"publisher","unstructured":"Liu, N., Zhou, Y. and Lee J.J. 2021. IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves. BMC Med Res Methodolt, 21(111). https:\/\/doi.org\/10.1186\/s12874-021-01308-8","DOI":"10.1186\/s12874-021-01308-8"},{"key":"1981_CR28","doi-asserted-by":"publisher","unstructured":"Sweeting, M. J. et al. 2023.Survival Extrapolation Incorporating General Population Mortality Using Excess Hazard and Cure Models: A Tutorial. Med Decis Making 43(6):737-748. https:\/\/doi.org\/10.1177\/0272989X231184247","DOI":"10.1177\/0272989X231184247"},{"issue":"1","key":"1981_CR29","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1080\/13696998.2021.1917139","volume":"24","author":"MA Chaudhary","year":"2021","unstructured":"Chaudhary, M. A. et al. 2021. Cost-effectiveness of nivolumab in squamous and non-squamous non-small cell lung cancer in Canada and Sweden: an update with 5-year data. Journal Of Medical Economics 24(1):607\u2013619.","journal-title":"Journal Of Medical Economics"},{"key":"1981_CR30","unstructured":"Apoteket. A Swedish state-owned chain (online), Accessed on Jan-2024. Available from: https:\/\/www.apoteket.se\/"},{"key":"1981_CR31","unstructured":"Socialstyrelsen. Viktlistor f\u00f6r NordDRG, Available from: https:\/\/www.socialstyrelsen.se\/statistik-och-data\/klassifikationer-och-koder\/drg\/viktlistor\/."},{"issue":"7","key":"1981_CR32","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1177\/0272989X241275969","volume":"44","author":"K Kim","year":"2024","unstructured":"Kim, K. et al. 2024. General Population Mortality Adjustment in Survival Extrapolation of Cancer Trials: Exploring Plausibility and Implications for Cost-Effectiveness Analyses in HER2-Positive Breast Cancer in Sweden. Medical Decision Making 44(7):843\u2013853.","journal-title":"Medical Decision Making"}],"container-title":["The European Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-026-01981-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10198-026-01981-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-026-01981-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T20:02:39Z","timestamp":1787342559000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10198-026-01981-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":32,"alternative-id":["1981"],"URL":"https:\/\/doi.org\/10.1007\/s10198-026-01981-w","relation":{},"ISSN":["1618-7598","1618-7601"],"issn-type":[{"value":"1618-7598","type":"print"},{"value":"1618-7601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"assertion":[{"value":"28 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}